Oral alternatives have been in development for years. Lucerastat falls into a different category called substrate reduction therapy (SRT).

Instead of supplying the missing enzyme, SRT aims to slow the body's production of the substance that accumulates. In Fabry, that means dialing back upstream synthesis of glycolipids so less Gb3 forms in the first place.

Patients swallow a small-molecule drug rather than visiting an infusion center every fortnight, a meaningful quality-of-life difference for people already managing a chronic disease.

What did the new study involve?

The Nature paper reports a phase 3 randomized trial, the kind of large, late-stage study regulators use to decide on approval. "Randomized" means a computer assigned each participant to receive either lucerastat or a comparator by chance, a design that reduces the influence of selection bias on outcomes.

"Pivotal" signals that the trial supplies the main evidence a regulator needs to weigh benefit and risk. After the controlled phase ended, patients rolled into an open-label extension.

In an open-label extension, both participants and investigators know who takes the drug, and the goal is to gather longer-term safety and tolerability information than the main trial allowed. Together, the two phases give both a controlled efficacy reading and an extended safety profile in one package.

Why publish in Nature?

A pivotal phase 3 dataset from a rare-disease candidate appearing in a broad-audience journal signals interest beyond the specialist clinic.

Few oral therapies for Fabry have reached this stage. Combining the randomized comparison with an open-label extension gives readers a controlled efficacy reading plus longer-term safety signals in a single package, an unusual level of completeness for a rare-disease publication.

What questions remain?

Reporting a pivotal study does not by itself guarantee regulatory approval. The U.S. Food and Drug Administration and the European Medicines Agency evaluate submitted data on their own timelines.

Sponsors must show clinically meaningful benefit on hard outcomes such as kidney function, measured by estimated glomerular filtration rate (eGFR), and cardiac structure, alongside improvements in biomarkers such as plasma lyso-Gb3.

Phase 3 trials in slowly progressive rare diseases often face statistical power challenges because so few patients are available to enroll, which can blur the interpretation of any one endpoint.

Readers who want the actual endpoint numbers, subgroup results, and adverse event counts will need to read the full Nature manuscript, where the primary endpoint results, secondary endpoints, and safety profile are spelled out in detail.